Scientists have realized a whole new treatment method that ”helps very ill Coronavirus patients recover in 72 hours.”
Experts say they have evidence that seriously ill coronavirus patients can be helped by infusions of blood plasma accumulated from people who have recovered from the disease and approval has now already been provided to University Hospital Erlangen, Germany, to produce therapeutic plasma to treat critically ill COVID-19 patients.
Two groups of medical professionals working at separate hospitals in China gave antibody-rich plasma from recovered patients to 15 severely Coronavirus ill patients and reported striking improvements in many of them within 3 days.
In one pilot study, medical doctors in Wuhan, China, gave “convalescent plasma” to 10 severely ill patients and found that virus levels in their bodies decreased fast. Within 72 hours, the medical doctors discovered improvements in the patients’ symptoms, ranging from difficulty breathing and also chest pains to fever and cough .
The remedy known as Convalescent plasma treatments date back to the 1918 Spanish flu pandemic. The therapy depends on the fact that individuals who have recovered from a viral infection have antibodies in their blood that can rapidly identify and destroy the virus the next time it attacks.
Professor David Tappin, a senior research fellow at the University of Glasgow, has applied to the UK’s National Institute for Health Research to run a pair of clinical trials with convalescent plasma.
“The outcomes are also encouraging for these patients,” he stated. But he added that to be sure plasma improved on the natural course of the disease and that it was safe in larger groups of patients, formal trials had to take place.
Professor Munir Pirmohamed, the president of the British Pharmacological Society, says the treatment should be carefully examined.
“This was not a randomized trial and all patients also received other treatments including antivirals such as remdesivir, which are currently in trials for COVID-19,” he said.
“It is also important to remember that there are potential safety concerns with convalescent plasma, including transmission of other agents and antibody enhancement of disease,” he added. “Even if shown to work, scalability to treat large numbers of patients may become an issue.”